New pill plus immunotherapy shows promise for Hard-to-Treat cancers

NCT ID NCT06362369

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 18 times

Summary

This study tests an experimental oral drug called 7HP349 (Alintegimod) combined with standard immunotherapy drugs (ipilimumab and nivolumab) in adults with advanced solid tumors like melanoma, lung, kidney, or liver cancer that have not responded to prior treatments. The goal is to find safe doses and see if the combination works better than standard therapy. About 126 participants will take part in two phases: first to check safety, then to compare effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brown University Health Cancer Institute

    RECRUITING

    Providence, Rhode Island, 02906, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dartmouth Hitchcock

    RECRUITING

    Lebanon, New Hampshire, 03756, United States

    Contact

    Contact Phone: •••-•••-••••

  • Florida Cancer Specialists

    COMPLETED

    Lake Mary, Florida, 32746, United States

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Phone: •••-•••-••••

  • University of Colorado Cancer Center

    RECRUITING

    Aurora, Colorado, 84005, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.